DNA methylation profiling of well‐differentiated thyroid cancer uncovers markers of recurrence free survival

Thyroid cancer is a heterogeneous disease with several subtypes characterized by cytological, histological and genetic alterations, but the involvement of epigenetics is not well understood. Here, we investigated the role of aberrant DNA methylation in the development of well‐differentiated thyroid tumors. We performed genome‐wide DNA methylation profiling in the largest well‐differentiated thyroid tumor series reported to date, comprising 83 primary tumors as well as 8 samples of adjacent normal tissue. The epigenetic profiles were closely related to not only tumor histology but also the underlying driver mutation; we found that follicular tumors had higher levels of methylation, which seemed to accumulate in a progressive manner along the tumorigenic process from adenomas to carcinomas. Furthermore, tumors harboring a BRAF or RAS mutation had a larger number of hypo‐ or hypermethylation events, respectively. The aberrant methylation of several candidate genes potentially related to thyroid carcinogenesis was validated in an independent series of 52 samples. Furthermore, through the integration of methylation and transcriptional expression data, we identified genes whose expression is associated with the methylation status of their promoters. Finally, by integrating clinical follow‐up information with methylation levels we propose etoposide‐induced 2.4 and Wilms tumor 1 as novel prognostic markers related to recurrence‐free survival. This comprehensive study provides insights into the role of DNA methylation in well‐differentiated thyroid cancer development and identifies novel markers associated with recurrence‐free survival.

[1]  Gustavo F. Bayón,et al.  DNA methylation signatures identify biologically distinct thyroid cancer subtypes. , 2013, The Journal of clinical endocrinology and metabolism.

[2]  Timothy E. Reddy,et al.  Dynamic DNA methylation across diverse human cell lines and tissues , 2013, Genome research.

[3]  M. Pelizzo,et al.  Differential gene expression of medullary thyroid carcinoma reveals specific markers associated with genetic conditions. , 2013, The American journal of pathology.

[4]  Q. Tao,et al.  Epigenetic silencing of the 3p22 tumor suppressor DLEC1 by promoter CpG methylation in non-Hodgkin and Hodgkin lymphomas , 2012, Journal of Translational Medicine.

[5]  T. H. van der Kwast,et al.  Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer , 2012, Epigenetics.

[6]  S. Lam,et al.  Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression , 2012, Genome research.

[7]  M. Hoque,et al.  Correlation between BRAF mutation and promoter methylation of TIMP3, RARβ2 and RASSF1A in thyroid cancer , 2012, Epigenetics.

[8]  P. Soares,et al.  mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. , 2012, The Journal of clinical endocrinology and metabolism.

[9]  L. D. White,et al.  Genomic Hypomethylation in the Human Germline Associates with Selective Structural Mutability in the Human Genome , 2012, PLoS genetics.

[10]  H. Kitchener,et al.  The Dynamics and Prognostic Potential of DNA Methylation Changes at Stem Cell Gene Loci in Women's Cancer , 2012, PLoS genetics.

[11]  Andreu Alibés,et al.  HumMeth27QCReport: an R package for quality control and primary analysis of Illumina Infinium methylation data , 2011, BMC Research Notes.

[12]  P. Hou,et al.  Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells. , 2011, Endocrine-related cancer.

[13]  M. Borrello,et al.  Evidence of oncogene-induced senescence in thyroid carcinogenesis. , 2011, Endocrine-related cancer.

[14]  Ratnesh K Singh,et al.  Inactivation of CHEK1 and EI24 is associated with the development of invasive cervical carcinoma: Clinical and prognostic implications , 2011, International journal of cancer.

[15]  Marina N. Nikiforova,et al.  Molecular genetics and diagnosis of thyroid cancer , 2011, Nature Reviews Endocrinology.

[16]  Gavin Sherlock,et al.  DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. , 2011, Genome research.

[17]  Thomas Lengauer,et al.  A DNA methylation fingerprint of 1628 human samples. , 2011, Genome research.

[18]  Xiao Zhang,et al.  Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis , 2010, BMC Bioinformatics.

[19]  Hiroyuki Yamamoto,et al.  IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. , 2010, Carcinogenesis.

[20]  P. Laird,et al.  Analysis of the Association between CIMP and BRAFV600E in Colorectal Cancer by DNA Methylation Profiling , 2009, PloS one.

[21]  K. Gunderson,et al.  Genome-wide DNA methylation profiling using Infinium® assay. , 2009, Epigenomics.

[22]  Ramón Díaz-Uriarte,et al.  Pomelo II: finding differentially expressed genes , 2009, Nucleic Acids Res..

[23]  L. Horvath,et al.  DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma , 2008, British Journal of Cancer.

[24]  G. Robertson,et al.  Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. , 2008, Cancer research.

[25]  B. Zhu,et al.  Do Benign Thyroid Nodules Have Malignant Potential? An Evidence-Based Review , 2008, World Journal of Surgery.

[26]  J. Dopazo,et al.  Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information , 2008, Oncogene.

[27]  D. Faller,et al.  Loss of putative tumor suppressor EI24/PIG8 confers resistance to etoposide , 2007, FEBS letters.

[28]  Minoru Toyota,et al.  Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer , 2007, Proceedings of the National Academy of Sciences.

[29]  M. Santoro,et al.  Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. , 2007, The Journal of clinical endocrinology and metabolism.

[30]  J. Califano,et al.  Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer , 2006, International journal of cancer.

[31]  M. Fraga,et al.  Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. , 2006, Cancer research.

[32]  P. Laird,et al.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer , 2006, Nature Genetics.

[33]  S. Asa,et al.  Pathogenetic mechanisms in thyroid follicular-cell neoplasia , 2006, Nature Reviews Cancer.

[34]  P. Ladenson,et al.  BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. , 2005, The Journal of clinical endocrinology and metabolism.

[35]  David E. Misek,et al.  Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis , 2005, Oncogene.

[36]  J. Shay,et al.  BRAFE600-associated senescence-like cell cycle arrest of human naevi , 2005, Nature.

[37]  W. Hiddemann,et al.  Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia , 2005, Leukemia.

[38]  E. Diamandis,et al.  The emerging roles of human tissue kallikreins in cancer , 2004, Nature Reviews Cancer.

[39]  P. Ladenson,et al.  Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. , 2003, Cancer research.

[40]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[41]  O. Hrusak,et al.  Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry , 2002, Leukemia.

[42]  G. Pfeifer,et al.  Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. , 2002, Cancer research.

[43]  M. Yatin,et al.  Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status. , 1999, The Journal of clinical endocrinology and metabolism.

[44]  D. Woods,et al.  Senescence of human fibroblasts induced by oncogenic Raf. , 1998, Genes & development.

[45]  E Gabrielson,et al.  Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M. Medvedovic,et al.  Studies of allelic loss in thyroid tumors reveal major differences in chromosomal instability between papillary and follicular carcinomas. , 1998, The Journal of clinical endocrinology and metabolism.

[47]  P. Laird,et al.  Genome-scale analysis of aberrant DNA methylation in colorectal cancer. , 2012, Genome research.

[48]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[49]  S. Formenti,et al.  Recombinant alpha2(IV)NC1 domain inhibits tumor cell-extracellular matrix interactions, induces cellular senescence, and inhibits tumor growth in vivo. , 2005, The American journal of pathology.

[50]  S. Formenti,et al.  Recombinant (cid:2) 2(IV)NC1 Domain Inhibits Tumor Cell-Extracellular Matrix Interactions, Induces Cellular Senescence, and Inhibits Tumor Growth in Vivo , 2005 .

[51]  M. Saji,et al.  Carcinoma Overexpression and Overactivation of Akt in Thyroid Updated , 2001 .